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INTRODUCTION:  Uterine  leiomyosarcoma  is a rare  uterine  malignancy.  Most  of the patients  lack symptoms
or present  with  a  rapidly  enlarging  pelvic  mass.
PRESENTATION  OF  CASE:  We  report  on a  very  large  leiomyosarcoma  in  a woman  presenting  with  a  3
months  history  of rapidly  growing  adominal  mass  and  fatigue.  Laparotomy  was performed  and  diagnosis
was conﬁrmed  by pathologic  and histologic  analysis.  Patient  refused  chemotherapy  after  surgery  andeywords:
eiomyosarcoma
ize
eiomyoma
died  from  recurrence  at 4th  postoperative  month.
DISCUSSION: Uterine  leiomyosarcomas  may  follow  a rapid  clinical  course  with  a doubling  time  of  four
weeks.  There  is no  reliable  method  to distinguish  uterine  sarcoma  from  benign  leiomyomas  preopera-
tively.
CONCLUSION:  This  case  represents  the  largest  leiomyosarcoma  reported  in  the  literature.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Leiomyosarcomas (LMS) are rare malignancies of uterus that
ccount for only 1–2% of all uterine malignancies [1,2]. Most women
ith LMS lack symptoms or present with a rapidly enlarging pelvic
ass [3]. In most cases, the diagnosis of leiomyosarcoma is made by
athological examination of hysterectomy or myomectomy spec-
men [4,5]. The incidence of LMS  in a series of hysterectomies
erformed for presumed uterine leiomyomas is approximately
.1–0.3% [6].
The cornerstone of the treatment for LMS  is surgery. The resec-
ion of the localised disease by hysterectomy is regarded as a gold
tandard. Pelvic and para-aortic lymphadenectomy is not routinely
ndicated. The incidence of lymphatic spread is only about 3% in
arly-stage uterine LMS  [4,7]. However, lymph-node involvement
s often present in the advanced disease. Chemotherapy or pelvic
adiation may  be considered following surgery. However, whether
ny form of adjuvant therapy improves survival compared with
bservation is unknown. Although the majority of women have a
terus-limited disease at the time of diagnosis, patients are at a
ubstantial risk for both local and distant recurrence of the disease.
Herein, we report a case of a leiomyosarcoma of the uterus
eighed 57 kg with a diameter of 40 cm.  To the best of our knowl-
dge, this case presents the largest leiomyosarcoma reported in the
iterature.
∗ Corresponding author at: Palmiye Caddesi, Turkuaz Sitesi, A22- B blok, Daire no:
3,  Atakoy 7, Kisim/Bakirkoy, Istanbul/Turkey.
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ttp://dx.doi.org/10.1016/j.ijscr.2015.12.042
210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Presentation of case
A 62-year-old, grand multiparous woman presented at our clinic
with complaints of enlarged mass and fatigue for last 3 months. She
had no signiﬁcant medical or family history and she had used no
medications. She has a body mass index (BMI) of 41.2 kg/m2 (Fig. 1).
Physical examination revealed a huge, palpable, mass with
restricted mobility in whole abdomen from symphysis pubis to up
to the level of the processus xiphoideus, with associated tender-
ness. Laboratory studies showed an elevated cancer antigen 125
(CA-125) level of 557 U/ml. All other laboratory tests, including CA
19-9, CEA, AFP were within normal limits.
Transabdominal ultrasonography revealed a complex mass with
solid areas, measuring more than 25 × 25 cm.  Because of anxiety,
MR or computered tomography (CT) imaging was not available.
The patient underwent surgery with the presumed diagnosis of
an ovarian or uterin malignancy. Exploratory laparatomy revealed
a huge uterine mass similar to that of a leiomyoma. A total hysterec-
tomy and bilateral salpingooopherectomy were performed (Fig. 2).
Gross characteristics of the mass such as loss of the whorl pat-
tern, homogeneous texture, yellow color and soft consistency felt
different than a leiomyoma. Intraoperative frozen section analyses
suggested of a high grade leiomyosarcoma. The surgery included
peritoneal washing, omentectomy, systematic pelvic and paraaor-
tic lymphadenectomy and peritoneal biopsies.
The removed uterus measured 68 × 55 × 33 cm and weighed
59 kg, while the mass measured 27 × 42 × 30 cm and weighed 57 kg
(Fig. 3).
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Fig. 1. Preoperative view of the patient in supine position.
Fig. 2. Intraoperative view of the uterus.
Fig. 3. Gross appearance of the tumor.Fig. 4. Majority of the tumor cell nuclei stained with Ki67 proliferation marker
(immunohistochemistry) × 100.
Postoperative histopathological evaluation showed large areas
of necrosis and increased mitotic activity. Tumor cells were spin-
dle shaped, pleomorphic and had moderate to severe atypia. There
was no evidence of lymph node metastasis and peritoneal involve-
ment. Immunohistochemical study with antibodies against p16,
p53 and Ki-67 were performed and 64% of cells were positive for
Ki-67 (Fig. 4).
Chemotherapy was recommended to patient, but she refused
the treatment. Metastatic tumors appeared on intestinal serosa and
abdominal wall after surgery. Her condition deteriorated rapidly
and patient died from recurrence of LMS  at 4th postoperative
month.
Written informed consent was  obtained from the patient shortly
after the surgery for publication of this case report.
3. DiscussionUterine LMSs are rare uterine malignancies [1]. However, the
incidence of sarcoma is 1–2% in postmenopausal women [8].
LMS  is an aggressive tumor associated with a high risk of recur-
rence and death, regardless of stage at presentation and differ
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rom other types of endometrial cancer [9]. Currently, there is
o reliable method to differentiate uterine leiomyosarcoma from
enign leiomyomas preoperatively. The diagnosis of leiomyosar-
oma should be suspected when severe pelvic pain accompanies a
elvic tumor, in a postmenopausal woman particularly [9].
Uterine leiomyosarcomas may  follow a rapid clinical course
ith a doubling time of four weeks [8]. Our patient had noticed
he growth of abdomen which had been carrying 57 kg of sarcoma,
ust 3 months before the surgery.
LMS, like all other endometrial cancers, is surgically staged.
urgical staging should include a hysterectomy and a BSO with
he resection of any visible metastatic disease. 60% of the women
ith LMS  present with the disease limited to the uterus upon ﬁrst
iagnosis [5]. Cure rates of these patients range from 20 to 60%,
epending on the success of the primary resection [7]. Several
ase series support the role of primary surgery [10,11]. Surgical
ytoreduction is associated with progression-free survival (PFS);
owever, it is not associated with overall survival (OS). As such, the
orbidity of surgery must be weighed against the improvement
n PFS [12]. In the largest series involving 46 patients with LMS, a
omplete cytoreduction was signiﬁcantly associated with disease-
ree survival (p = 0.03) [11]. Ovarian preservation can be considered
n premenopausal patients with early-stage LMS  of the uterus. In a
tudy of 341 women less than 50 years old who  were stage I or II
MS at diagnosis, no difference was found in the ﬁve-year disease-
ree survival between those who did and did not undergo a BSO [13].
e performed a BSO in this case as the patient had postmenapausal
tatus.
However, sarcomas are aggressive tumors with a high risk of
ocal and distant relapse even in completely resected tumours
2,14]. Patients with even International Federation of Gynecology
nd Obstetrics (FIGO) stages I and II LMS  have a very high risk of
ecurrence. Survival after recurrence is poor. In one study, the 5-
ear survival rate for women with 1988 FIGO stage I LMS (tumour
imited to the uterus) was only 51%, and for patients with stage
I LMS  (tumour in uterus and cervix), the 5-year survival rate was
5% [15]. The relapse rate is approximately 70% for stages I and
I. The site of metastasis or recurrence is often distant due to the
aematogenous spread into the lungs or liver [5].
Radiation therapy appears to have little beneﬁt in the treatment
f early-stage LMS. A retrospective review from the Surveillance,
pidemiology and End Results database of women with stage I/II
MS  demonstrated no survival beneﬁt from adjuvant radiation
herapy [16]. There are few prospective data on the utility of
hemotherapy for stage I/II LMS. A prospective study has demon-
trated thet the combination chemotherapy of gemcitabine and
ocetaxel followed by doxorubicin offers a survival beneﬁt to
terine leiomyosarcoma patients [17]. Our patient chose to reject
hemotherapy despite our recommendation.
To the best of our knowledge, no case describing a similar size
f leiomyosarcoma has been described in the English literature.
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